Material Overview: Properties of Glass and Plastic in Pharma

Glass: Glass, particularly Type I borosilicate, is chemically inert, impermeable, and thermally stable. It’s widely used in parenteral packaging and products with high sensitivity.

Plastic: Common plastics include HDPE, PET, and PP. They offer lighter weight and better resistance to breakage but are more permeable to gases and moisture.

• Glass is suitable for high-risk, injectable formulations
• Plastic is preferred for solid or oral liquid dosage forms

Chemical Compatibility and Reactivity

One of the most critical selection criteria is the interaction between the container and the drug product. Glass is non-reactive but may release trace alkali (in Type II or III) in some conditions. Plastic, on the other hand, may:

• Leach additives (plasticizers, antioxidants)
• Absorb or adsorb active ingredients
• React with solvents or volatile excipients

Compatibility studies are essential regardless of the material type. Testing should include leachables, extractables, and sorption assessments.

Barrier Properties: Moisture and Oxygen Transmission

Moisture ingress and oxygen permeability are major concerns during long-term storage.

• Glass: Offers complete barrier protection against water vapor and oxygen
• Plastic: Materials like HDPE have relatively high WVTR (water vapor transmission rate), while PET has better barrier properties

For sensitive formulations, glass or multilayer plastic with barrier coatings is preferred. Use appropriate desiccants in plastic packaging to reduce moisture uptake risk.

Mechanical Durability and Breakage Risk

Glass is fragile and prone to breakage during transport or handling, especially in high-speed filling lines or drop tests. Plastic is:

• Impact-resistant
• Lighter in weight
• Less costly to ship and store

For pediatric, geriatric, or field-use products, plastic often enhances patient and packaging safety.

Photostability and Light Protection

Amber glass provides high UV protection, making it ideal for photolabile drugs. In contrast:

• Plastic may need additional pigments or UV-blocking agents
• Opaque polymers (like black HDPE) are used when UV exposure is critical

Ensure ICH Q1B photostability testing is performed with final container type to evaluate light-related degradation risk.

Case Study: Vitamin Solution in PET vs. Glass

In a comparative study, a multivitamin oral solution stored in PET bottles showed 7% degradation at 3 months (40°C/75% RH), while the same product in amber Type I glass retained 98% potency. The oxygen permeability of PET contributed to oxidative degradation. Result: manufacturer switched to glass for final packaging.

Regulatory Expectations and Submission Impact

According to CDSCO and ICH, packaging used in stability must reflect the marketed pack. Regulatory agencies expect:

• Extractables and leachables studies for plastic
• Glass delamination risk assessment (for glass)
• Material specification sheets and compliance (e.g., USP for plastic)
• Photostability, integrity, and aging data

Failure to justify container type can delay approvals or prompt deficiency letters.

Environmental Impact and Sustainability Considerations

As sustainability becomes a regulatory and market priority, container material choice also reflects environmental responsibility.

• Glass: 100% recyclable, inert, and reusable—but energy-intensive to produce
• Plastic: Lower energy production cost but may generate microplastics and requires recycling infrastructure

Some companies opt for bio-based plastics or recyclable HDPE as a sustainable alternative when stability allows.

Cost and Supply Chain Factors

Cost can be a deciding factor when technical performance is equivalent:

• Plastic containers generally cost less in manufacturing and transportation
• Glass containers require specialized handling, packaging, and higher QA oversight
• Long lead times and regional supply dependencies can affect availability of both materials

Balance between cost and compliance is essential—cutting costs at the expense of protection often leads to regulatory delays.

When to Use Glass Over Plastic

• Parenteral dosage forms
• Highly moisture- or oxygen-sensitive APIs
• Long shelf-life products requiring complete barrier protection
• Regulatory submissions where robust data is essential

When Plastic Is a Better Choice

• Oral liquids or tablets with moderate sensitivity
• Patient-friendly packaging needs (e.g., squeezability, safety)
• Field or ambulatory settings with rough handling
• Cost-sensitive generics or short-shelf-life products

Stability Study Design: Considerations for Both Materials

Whether using glass or plastic, follow these best practices:

• Test containers under ICH long-term and accelerated conditions
• Include photostability and CCI tests in validation
• Conduct migration and sorption studies
• Ensure sealing compatibility with closures
• Perform mechanical testing under simulated transport stress

Refer to GMP guidelines to align packaging qualification with regulatory expectations.

Summary Comparison Table

Conclusion

Choosing between glass and plastic containers for long-term pharmaceutical storage requires a nuanced understanding of product properties, regulatory expectations, and logistical challenges. While glass offers unmatched protection and regulatory acceptance, plastic provides practical benefits in cost and safety. The right decision depends on balancing technical performance with compliance, sustainability, and patient use requirements.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP : Plastic Packaging Systems
• USP : Assessment of Extractables
• FDA Guidance for Industry: Container Closure Systems
• WHO Guidelines on Packaging Materials for Pharmaceuticals

Role of Container Type in Stability Testing

During ICH stability studies, the container becomes the product’s primary defense against environmental stressors such as heat, humidity, light, and oxygen. Regulatory guidelines require that stability data be generated using the actual market-intended container closure system (CCS). Thus, choosing the wrong container can invalidate the stability results altogether.

Refer to ICH guidelines for container-specific stability recommendations.

Common Container Types in Pharmaceutical Packaging

Let’s look at the common container types and their respective pros and cons in the context of stability:

• Glass Vials (Type I): Highly inert and impermeable, ideal for injectables and sensitive APIs.
• Plastic Bottles (HDPE, PET): Common for oral liquids and solids, but more permeable to moisture and gases.
• Blister Packs (PVC, PVDC, Aclar): Great for unit-dose formats, require evaluation for delamination and seal integrity.
• Ampoules: Hermetically sealed glass, excellent for light and oxygen-sensitive solutions.
• Sachets and Pouches: Used for powders and granules, but prone to puncture and moisture ingress.

Key Factors Affected by Container Type

The choice of container influences several critical stability outcomes:

1. Assay and Degradation: Some plastic containers can adsorb or leach chemicals, altering API levels.
2. Moisture Uptake: Non-glass containers may allow water ingress, accelerating hydrolysis.
3. Oxygen Permeation: HDPE bottles and some blister films may not provide adequate oxygen barriers.
4. Light Protection: Amber glass offers better protection than transparent polymers.
5. Migration of Additives: Plasticizers and stabilizers may migrate into the drug product.

These effects must be simulated in forced degradation and long-term studies to assess real-world performance.

Comparative Study Example: Glass vs Plastic for Oral Solutions

In a comparative study of a vitamin C oral solution, batches stored in Type I glass showed less than 1% assay loss at 3 months under 40°C/75% RH. Meanwhile, the same solution in PET bottles degraded by nearly 5%, attributed to oxygen ingress through the polymer. This illustrates how material permeability influences stability—even when both containers meet pharmacopeial standards.

Checklist for Evaluating Container Type During Development

• Chemical compatibility with formulation (avoid reactivity)
• Water vapor transmission rate (WVTR)
• Oxygen transmission rate (OTR)
• Resistance to light, breakage, and stress
• Closure system compatibility and sealing integrity
• Suitability for sterilization (if required)
• Global regulatory acceptability

These parameters should be evaluated under simulated transport and storage conditions before final selection.

Regulatory Expectations for Container Selection

Regulators like the USFDA and EMA mandate that stability data must reflect the final market presentation. If a different container is used during R&D, bridging studies or justifications are required in the dossier.

• Include extractables and leachables studies (USP , )
• Document justification for container choice
• Provide validation reports for sealing and integrity

These records should appear in CTD Module 3.2.P.7 of the regulatory submission.

How to Conduct Compatibility Testing Based on Container Type

Container compatibility must be tested throughout the product lifecycle. Key test methods include:

• Assay and impurity profile trending over time
• Leachables identification using LC-MS, GC-MS, ICP-MS
• Stress testing at ICH conditions (30°C/65% RH, 40°C/75% RH)
• Photostability testing per ICH Q1B
• Container Closure Integrity Testing (CCI) for sterile products

These studies must use samples stored in the exact packaging system proposed for commercial use.

Case Study: Impact of Closure Incompatibility with Plastic Vials

A company conducted a stability study for a pediatric oral antibiotic in plastic vials with screw caps. After three months at 30°C/75% RH, drug loss and microbial contamination were observed. Investigation revealed incomplete sealing due to torque loss under heat expansion. Switching to an induction-sealed cap resolved the issue and ensured container closure integrity (CCI).

This reinforces the need to validate closures in conjunction with container material and product formulation.

Tips for Selecting the Right Container Type Based on Product Class

• Injectables: Type I glass vial or ampoule + rubber stopper + aluminum seal
• Oral liquids: Amber glass or PET bottle + child-resistant cap
• Solid dose forms: PVC/PVDC blister or HDPE bottle with desiccant
• Topicals: Laminate tubes or high-barrier plastic jars
• Inhalers: Aluminum canister with metered dose valve

Always assess container impact on dosage delivery, not just physical stability.

Internal Documentation Requirements for Container Type Evaluation

Ensure the following documents are included in your packaging development file:

• Material specifications and vendor CoAs
• Summary of compatibility studies
• CCI validation reports
• Visual inspection protocols and sealing SOPs
• Photostability and migration test reports
• Packaging description in the stability protocol

Refer to Pharma SOPs for templates to document packaging qualification steps.

Link Between Container Selection and Product Shelf Life

Suboptimal containers can shorten shelf life by accelerating degradation. For instance, polyethylene containers with high moisture permeability may reduce a hygroscopic API’s shelf life from 24 to 12 months. On the contrary, blister packs with Aclar films or glass containers can extend shelf life by reducing environmental exposure.

Hence, container choice is a shelf-life defining factor—not just a packaging decision.

Conclusion

The container type used in pharmaceutical stability testing can make or break a product’s success. By evaluating chemical compatibility, moisture/oxygen permeability, mechanical protection, and regulatory compliance, pharma professionals can select the right packaging solution that ensures product integrity throughout the shelf life. Always integrate container evaluation into the early stages of formulation development and document findings rigorously.

References:

• ICH Q1A(R2) Stability Testing of New Drug Substances and Products
• ICH Q1B Photostability Testing of New Drug Substances and Products
• USP : Containers – Plastics
• USP : Assessment of Extractables
• FDA Guidance for Industry – Container Closure Systems
• EMA Guideline on Plastic Immediate Packaging Materials